Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Deffered Revenue: 2017-2024

Historic Non-Current Deffered Revenue for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $234.0 million.

  • Arcus Biosciences' Non-Current Deffered Revenue fell 81.66% to $53.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0 million, marking a year-over-year decrease of 81.66%. This contributed to the annual value of $234.0 million for FY2024, which is 23.78% down from last year.
  • Per Arcus Biosciences' latest filing, its Non-Current Deffered Revenue stood at $234.0 million for FY2024, which was down 23.78% from $307.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Non-Current Deffered Revenue registered a high of $462.0 million during FY2021, and its lowest value of $132.5 million during FY2020.
  • In the last 3 years, Arcus Biosciences' Non-Current Deffered Revenue had a median value of $307.0 million in 2023 and averaged $298.7 million.
  • As far as peak fluctuations go, Arcus Biosciences' Non-Current Deffered Revenue surged by 1,002.42% in 2020, and later decreased by 23.78% in 2024.
  • Yearly analysis of 5 years shows Arcus Biosciences' Non-Current Deffered Revenue stood at $132.5 million in 2020, then spiked by 248.59% to $462.0 million in 2021, then dropped by 23.16% to $355.0 million in 2022, then declined by 13.52% to $307.0 million in 2023, then decreased by 23.78% to $234.0 million in 2024.